Organ Recipients Don't Realize Skin Cancer Risk

2006 ◽  
Vol 37 (7) ◽  
pp. 52
Author(s):  
BETSY BATES
Keyword(s):  
Skin Cancer ◽  
Cancer Risk ◽  
Skin Cancer Risk

scholarly journals Photosensitizing Medications and Skin Cancer: A Comprehensive Review

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2344
Author(s):  
Elisabeth A. George ◽  
Navya Baranwal ◽  
Jae H. Kang ◽  
Abrar A. Qureshi ◽  
Aaron M. Drucker ◽  
...  
Keyword(s):  
Skin Cancer ◽  
Cancer Risk ◽  
Cell Carcinoma ◽  
The United States ◽  
In Vivo Studies ◽  
Cancer Risk Factors ◽  
Skin Cancer Risk ◽  
Number Of Patients

(1) The incidence of skin cancer is increasing in the United States (US) despite scientific advances in our understanding of skin cancer risk factors and treatments. In vitro and in vivo studies have provided evidence that suggests that certain photosensitizing medications (PSMs) increase skin cancer risk. This review summarizes current epidemiological evidence on the association between common PSMs and skin cancer. (2) A comprehensive literature search was conducted to identify meta-analyses, observational studies and clinical trials that report on skin cancer events in PSM users. The associated risks of keratinocyte carcinoma (squamous cell carcinoma and basal cell carcinoma) and melanoma are summarized, for each PSM. (3) There are extensive reports on antihypertensives and statins relative to other PSMs, with positive and null findings, respectively. Fewer studies have explored amiodarone, metformin, antimicrobials and vemurafenib. No studies report on the individual skin cancer risks in glyburide, naproxen, piroxicam, chlorpromazine, thioridazine and nalidixic acid users. (4) The research gaps in understanding the relationship between PSMs and skin cancer outlined in this review should be prioritized because the US population is aging. Thus the number of patients prescribed PSMs is likely to continue to rise.

scholarly journals Association of Environmental Arsenic Exposure, Genetic Polymorphisms of Susceptible Genes, and Skin Cancers in Taiwan

2015 ◽  
Vol 2015 ◽  
pp. 1-10 ◽  
Author(s):  
Ling-I Hsu ◽  
Meei-Maan Wu ◽  
Yuan-Hung Wang ◽  
Cheng-Yeh Lee ◽  
Tse-Yen Yang ◽  
...  
Keyword(s):  
Skin Cancer ◽  
Cancer Risk ◽  
Arsenic Exposure ◽  
Skin Carcinogenesis ◽  
Glutathione S Transferase ◽  
Xenobiotic Detoxification ◽  
Skin Cancer Risk ◽  
Metabolic Genes ◽  
Skin Cancers ◽  
And Gender

Deficiency in the capability of xenobiotic detoxification and arsenic methylation may be correlated with individual susceptibility to arsenic-related skin cancers. We hypothesized that glutathione S-transferase (GST M1, T1, and P1), reactive oxygen species (ROS) related metabolic genes (NQO1, EPHX1, and HO-1), and DNA repair genes (XRCC1, XPD, hOGG1, and ATM) together may play a role in arsenic-induced skin carcinogenesis. We conducted a case-control study consisting of 70 pathologically confirmed skin cancer patients and 210 age and gender matched participants with genotyping of 12 selected polymorphisms. The skin cancer risks were estimated by odds ratio (OR) and 95% confidence interval (CI) using logistic regression. EPHX1 Tyr113His, XPD C156A, and GSTT1 null genotypes were associated with skin cancer risk (OR = 2.99, 95% CI = 1.01–8.83; OR = 2.04, 95% CI = 0.99–4.27; OR = 1.74, 95% CI = 1.00–3.02, resp.). However, none of these polymorphisms showed significant association after considering arsenic exposure status. Individuals carrying three risk polymorphisms of EPHX1 Tyr113His, XPD C156A, and GSTs presented a 400% increased skin cancer risk when compared to those with less than or equal to one polymorphism. In conclusion, GSTs, EPHX1, and XPD are potential genetic factors for arsenic-induced skin cancers. The roles of these genes for arsenic-induced skin carcinogenesis need to be further evaluated.

Skin Cancer Risk Behaviors

2005 ◽  
Vol 141 (8) ◽  
Author(s):  
Joel Hillhouse ◽  
Rob Turrisi
Keyword(s):  
Skin Cancer ◽  
Cancer Risk ◽  
Risk Behaviors ◽  
Skin Cancer Risk

scholarly journals Use of hydrochlorothiazide and risk of skin cancer: a nationwide Taiwanese case–control study

2019 ◽  
Vol 121 (11) ◽  
pp. 973-978 ◽  
Author(s):  
Anton Pottegård ◽  
Sidsel Arnspang Pedersen ◽  
Sigrun Alba Johannesdottir Schmidt ◽  
Chaw-Ning Lee ◽  
Chao-Kai Hsu ◽  
...  
Keyword(s):  
Skin Cancer ◽  
Cancer Risk ◽  
Asian Population ◽  
Case Control ◽  
Sensitivity Analyses ◽  
Research Database ◽  
Lip Cancer ◽  
Skin Cancer Risk ◽  
Non Melanoma Skin Cancer ◽  
Melanoma Skin

Abstract Background The antihypertensive agent hydrochlorothiazide has been associated with increased risks of non-melanoma skin cancer (NMSC) and possibly some melanoma subtypes. Previous studies were, however, conducted in predominantly Caucasian populations. We therefore examined the association between hydrochlorothiazide and skin cancer risk in an Asian population. Methods By using Taiwan’s National Health Insurance Research Database (NHIRD), we conducted three separate case–control studies of lip cancer, non-lip non-melanoma skin cancer and melanoma. Cases (n = 29,082) with a first-ever skin cancer diagnoses (2008–2015) were matched 1:10 to population controls. We estimated odds ratios (ORs) associating hydrochlorothiazide use with skin cancer risk by using conditional logistic regression. Results Hydrochlorothiazide use showed no overall association with any of the three outcomes: ORs for high cumulative use of HCTZ (≥50,000 mg) were 0.86 (95% CI 0.09–7.81) for lip cancer, 1.16 (95% CI 0.98–1.37) for non-lip NMSC and 1.07 (95% CI 0.65–1.76) for melanoma. There was some evidence of a dose–response pattern for non-lip NMSC, with an OR of 1.66 (95% CI 0.82–3.33) for 100,000–149,999 mg of HCTZ. The null findings were robust across subgroup and sensitivity analyses. Conclusion Use of HCTZ appears safe in terms of skin cancer risk in an Asian population.

Sign in / Sign up

Export Citation Format

Share Document